江苏吴中(600200.SH):苏州制药厂获利奈唑胺葡萄糖注射液药品注册证书
格隆汇9月17日丨江苏吴中(600200.SH)公布,近日,公司全资子公司江苏吴中医药集团有限公司下属分支机构江苏吴中医药集团有限公司苏州制药厂收到了国家药监局核准签发的利奈唑胺葡萄糖注射液《药品注册证书》。
利奈唑胺是一种细菌蛋白质合成的抑制剂,其主要作用机制不同于氯霉素和林可霉素一样抑制肽基转移酶,主要通过与P位点结合,从而抑制细菌起始复合物的形成。这种独特的结构和作用机制,决定它与其他抗菌药物不易产生交叉耐药,对肽基转移酶抑制剂耐药的细菌依然有效。
利奈唑胺用于治疗甲氧西林耐药的阳性菌引起的感染,也是各国临床指南一致推荐的重症抗感染用药。目前上市的剂型有片剂(规格:600mg)、葡萄糖注射液(规格:100ml:利奈唑胺200mg与葡萄糖4.57g、300ml:利奈唑胺600mg与葡萄糖13.7g)、干混悬剂(5ml:100mg(每瓶含利奈唑胺3g))和氯化钠注射液(规格:600mg/300ml)。
根据PDB药物综合数据库的重点城市医院典型医院用药数据显示,利奈唑胺葡萄糖注射液2019年度销售金额约6.86亿元人民币。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.